Persist AI vs ElevenLabs

Side-by-side comparison of AI visibility scores, market position, and capabilities

ElevenLabs leads in AI visibility (84 vs 23)
Persist AI logo

Persist AI

EmergingHealthcare

General

AI-powered long-acting injectable drug formulation platform cutting development from 5 years to 2; $12M Series A with Eli Lilly investment competing in microsphere CDMO development.

AI VisibilityBeta
Overall Score
D23
Category Rank
#803 of 1158
AI Consensus
59%
Trend
up
Per Platform
ChatGPT
32
Perplexity
19
Gemini
28

About

Persist AI is a pharmaceutical formulation company operating an AI-powered drug formulation platform with robotic cloud lab capabilities — specializing in the development of long-acting injectable (LAI) microsphere formulations that can deliver drug release over weeks or months (up to one year), addressing the adherence challenges of daily oral medications for chronic conditions including mental health, addiction, HIV, contraception, and oncology. Founded in 2022 and backed by $16 million including a $12 million Series A led by Spero Ventures with participation from Eli Lilly, Persist AI accelerates drug development timelines by approximately 50%, reducing typical 5-year formulation development to 2 years.\n\nPersist AI's platform combines AI-driven formulation design (predicting which polymer/drug/process combinations will achieve target release profiles) with robotic laboratory execution (automated synthesis and testing of formulation candidates) and analytics that identify optimal formulations faster than traditional trial-and-error approaches. The microsphere technology encapsulates drug molecules in biodegradable polymer spheres that gradually release the drug as the polymer degrades — a proven technology (Risperdal Consta, Lupron Depot) but one that takes years to develop with traditional methods. Eli Lilly's participation as an investor signals pharma validation of the platform approach.\n\nIn 2025, Persist AI competes in the drug formulation and CDMO (contract development and manufacturing) market with EVO Pharma, Polymeropoulos (a long-acting injectable specialist), and larger CDMOs including Lonza and Catalent for LAI microsphere development services. The long-acting injectable market is growing as mental health conditions (schizophrenia, bipolar) see improved outcomes with LAI antipsychotics that eliminate the adherence problem — patients who receive monthly or quarterly injections have significantly better medication compliance than those taking daily pills. The 2025 strategy focuses on growing pharma company partnerships for LAI development projects, advancing internal pipeline candidates toward clinical trials, and building the manufacturing scale-up capabilities needed for commercial supply.

Full profile
ElevenLabs logo

ElevenLabs

ChallengerAI & Machine Learning

Voice AI

$500M Series D at $11B valuation (Feb 2026) — largest voice AI funding round ever. $330M ARR; 1M+ developers using the API. Enterprise customers: Deutsche Telekom, Revolut, Meta, Salesforce. Voices in 32 languages; real-time cloning from 1 second of audio.

AI VisibilityBeta
Overall Score
A84
Category Rank
#1 of 1
AI Consensus
64%
Trend
up
Per Platform
ChatGPT
79
Perplexity
89
Gemini
82

About

ElevenLabs was founded in 2022 by Piotr Dabkowski and Mati Staniszewski, two former Google and Palantir engineers who set out to break the language barrier using AI voice technology. The company specializes in AI-powered voice synthesis, cloning, and dubbing, enabling developers and enterprises to generate human-quality speech in over 30 languages. Its core technology combines deep learning models trained on massive speech datasets to produce natural-sounding voices indistinguishable from real humans.\n\nElevenLabs offers a suite of products including its flagship text-to-speech API, voice cloning tools, and an AI dubbing platform that localizes video content while preserving the speaker's original voice. Its products target a broad audience—from indie developers building audio apps to large enterprises deploying voice interfaces at scale. Key differentiators include ultra-low latency streaming synthesis, fine-grained voice customization, and a growing library of pre-built AI voices across accents and styles.\n\nElevenLabs has grown rapidly, surpassing $330M in annualized revenue and serving over 1 million developers. Enterprise clients include Deutsche Telekom, Spotify, and leading media companies. In February 2026, the company closed a $500M Series D at an $11B valuation, cementing its position as the market leader in AI voice. Its APIs power podcasts, audiobooks, video games, and customer service bots worldwide, making ElevenLabs the default infrastructure layer for AI-generated audio.

Full profile

AI Visibility Head-to-Head

23
Overall Score
84
#803
Category Rank
#1
59
AI Consensus
64
up
Trend
up
32
ChatGPT
79
19
Perplexity
89
28
Gemini
82
16
Claude
75
19
Grok
88

Key Details

Category
General
Voice AI
Tier
Emerging
Challenger
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only ElevenLabs
Voice AI

Integrations

Only ElevenLabs

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.